Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance Study of [14C]Azvudine in Healthy Male Subjects
NCT07002281Phase 1Completed
- Sponsor
- Genuine Biotech
- Start
- Jul 2024
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of azvudine in human immunodeficiency virus infection (HIV) and coronavirus disease 2019 (COVID-19), sponsored by Genuine Biotech. Primary endpoints: Maximum Concentration of total radioactive material in whole blood and plasma, Time to Maximum Concentration of total radioactive material in whole blood and plasma and 4 more. Started Jul 2024; status: completed.
02
Drugs
azvudine
03
Conditions
human immunodeficiency virus infection (HIV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07002281.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07002281.